BioCentury | Apr 3, 2021
Deals

April 2 Quick Takes: Agios begins share buybacks upon closing Servier deal, plus Royalty-GSK, Gracell-Lonza, Alloy, Eloxx-Zikani and Angelini-Ovid

Upon completing the sale of its cancer business to Servier for $1.8 billion up front and up to $200 million in milestones, Agios Therapeutics Inc. (NASDAQ:AGIO) announced plans to repurchase 7.1 million shares, or $344.5...
BioCentury | Apr 1, 2021
Product Development

COVID roundup: BioNTech-Pfizer vaccine protects adolescents; plus AZ, GSK-Novavax and Amazon

BioNTech SE (NASDAQ:BNTX) and Pfizer Inc. (NYSE:PFE) plan to request Comirnaty (BNT162b2) emergency use authorization amendments from FDA and EMA to include adolescents based on Phase III data showing no COVID-19 cases in subjects ages...
BioCentury | Apr 1, 2021
Product Development

Lilly-Vir mAb cocktail could expand treatment to low-risk COVID-19 patients

Top-line Phase II data for a combination of mAbs from Vir and Lilly could open the door to a mAb treatment for a new COVD-19 population: low-risk outpatients. Three mAb therapies have emergency use authorization...
BioCentury | Mar 27, 2021
Regulation

FDA approval solidifies bluebird’s anti-BCMA CAR T as ‘cornerstone’ of BMS’s multiple myeloma portfolio

FDA’s approval late Friday of Abecma idecabtagene vicleucel marks the second CAR T cell therapy BMS will bring to market as it continues to fill out its cancer portfolio ahead of revenue losses from...
BioCentury | Mar 27, 2021
Product Development

A Vir’s-eye view of the path forward for its COVID mAbs

As Vir gears up to be third to market with a COVID-19 mAb therapy, the company thinks its pipeline could see broader use than authorized products, and believes the class will become a mainstay even as variants...
BioCentury | Mar 26, 2021
Product Development

Next-generation checkpoint development surges as rare wins overshadow setbacks

Though the failure rate of next-generation checkpoints has far out-stripped that of the rare successes, companies have not been scared away from the search for the next blockbuster, or for a way to finally...
BioCentury | Mar 26, 2021
Regulation

CHMP backs GSK’s lupus drug for kidney complication, J&J’s oral MS therapy

GSK’s Benlysta and J&J’s Ponvory are two of the latest therapies to win support from EMA’s CHMP, which did not issue any negative recommendations in March. The agency recommended a label extension for Benlysta belimumab to treat active lupus...
BioCentury | Mar 26, 2021
Deals

AllianThera emerges with Insilico deal, team of pharma vets

Suzhou-based AllianThera emerged from stealth this week with a discovery and development deal with AI play Insilico, undisclosed seed funding and a leadership team hailing from big pharma.  The newco is led by long-time Pfizer...
BioCentury | Mar 25, 2021
Management Tracks

Slaoui stepping back from all biopharma roles, expresses ‘deep regrets’ following sexual harassment claim

Former Operation Warp Speed leader Moncef Slaoui implied that he is taking a leave of absence from all his professional roles following his termination as Galvani’s chairman by GSK due to sexual harassment allegations. Slaoui, a 30-year...
BioCentury | Mar 25, 2021
Product Development

Crucell veterans launch Leyden Labs with €40M to take antiviral nasal sprays toward clinic

Newly launched Leyden Labs is aiming to develop intranasal products that protect against infection by viral families that share common traits, offering broader coverage than vaccines against specific viruses or variants. The Dutch start-up has...
Items per page:
1 - 10 of 8570